As understanding of the human microbiome improves, novel therapeutic targets to improve human health with microbial therapeutics will continue to expand. We outline key considerations of balancing risks and benefits, optimising access, returning key results to research participants, and potential conflicts of interest.
Keywords: Clostridium difficile; FMT; ethics; fecal microbiota transplant; microbiome; recurrent Clostridium difficile.